Literature DB >> 20101522

Alternative complement pathway in schizophrenia.

Anna Boyajyan1, Aren Khoyetsyan, Andranik Chavushyan.   

Abstract

In the present study, we evaluated functional activity of the alternative pathway of complement in schizophrenia by measuring the alternative pathway hemolytic activity (AH50) of complement as well as hemolytic activity of the complement C3 component (C3H50) in the blood of patients with schizophrenia and healthy subjects. To assess the influence of neuroleptic treatment on measured parameters, both drug-free and medicated patients were examined. In addition, correlation analysis between AH50 and C3H50 has been performed. The results of the present study clearly demonstrate upregulation of the alternative complement cascade in schizophrenia and activator effect of neuroleptics on complement alternative pathway. Based upon the results obtained we hypothesize that hyperactivation of the alternative complement pathway in schizophrenia is stimulated by apoptotic cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101522     DOI: 10.1007/s11064-010-0126-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  40 in total

1.  The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens.

Authors:  A Cherukuri; P C Cheng; S K Pierce
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

2.  Response to C3a, mast cells, and asthma.

Authors:  Asifa K Zaidi; Yassine Amrani; Reynold A Panettieri; Hydar Ali
Journal:  FASEB J       Date:  2006-02       Impact factor: 5.191

3.  Enhancement of macrophage phagocytosis upon iC3b deposition on apoptotic cells.

Authors:  F Takizawa; S Tsuji; S Nagasawa
Journal:  FEBS Lett       Date:  1996-11-18       Impact factor: 4.124

Review 4.  Schizophrenia and bipolar disorder: findings from studies of the Stanley Foundation Brain Collection.

Authors:  M B Knable
Journal:  Schizophr Res       Date:  1999-09-29       Impact factor: 4.939

Review 5.  GSK-3 and the neurodevelopmental hypothesis of schizophrenia.

Authors:  Nitsan Kozlovsky; R H Belmaker; Galila Agam
Journal:  Eur Neuropsychopharmacol       Date:  2002-02       Impact factor: 4.600

6.  Classical pathway complement activity in schizophrenia.

Authors:  Svetlana Hakobyan; Anna Boyajyan; Robert B Sim
Journal:  Neurosci Lett       Date:  2005-02-01       Impact factor: 3.046

7.  Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia.

Authors:  L F Jarskog; J H Gilmore; E S Selinger; J A Lieberman
Journal:  Biol Psychiatry       Date:  2000-10-01       Impact factor: 13.382

8.  Complement: a novel factor in basal and ischemia-induced neurogenesis.

Authors:  Yalda Rahpeymai; Max Albert Hietala; Ulrika Wilhelmsson; Andrew Fotheringham; Ioan Davies; Ann-Katrin Nilsson; Jörg Zwirner; Rick A Wetsel; Craig Gerard; Milos Pekny; Marcela Pekna
Journal:  EMBO J       Date:  2006-02-23       Impact factor: 11.598

Review 9.  Schizophrenia as a disorder of neurodevelopment.

Authors:  David A Lewis; Pat Levitt
Journal:  Annu Rev Neurosci       Date:  2002-03-22       Impact factor: 12.449

Review 10.  Structure, function and cellular expression of complement anaphylatoxin receptors.

Authors:  R A Wetsel
Journal:  Curr Opin Immunol       Date:  1995-02       Impact factor: 7.486

View more
  12 in total

1.  Association of C1QB gene polymorphism with schizophrenia in Armenian population.

Authors:  Roksana Zakharyan; Aren Khoyetsyan; Arsen Arakelyan; Anna Boyajyan; Anaida Gevorgyan; Anna Stahelova; Frantisek Mrazek; Martin Petrek
Journal:  BMC Med Genet       Date:  2011-09-28       Impact factor: 2.103

Review 2.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

3.  C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients.

Authors:  Mohamed Jalloul Nsaiba; Marc Lapointe; Hajer Mabrouk; Wahiba Douki; Lotfi Gaha; Louis Pérusse; Claude Bouchard; Besma Bel Hadj Jrad; Katherine Cianflone
Journal:  Neurochem Res       Date:  2015-02-27       Impact factor: 3.996

Review 4.  The complement system in schizophrenia: where are we now and what's next?

Authors:  Julia J Woo; Jennie G Pouget; Clement C Zai; James L Kennedy
Journal:  Mol Psychiatry       Date:  2019-08-22       Impact factor: 15.992

5.  Charting the proteome landscape in major psychiatric disorders: From biomarkers to biological pathways towards drug discovery.

Authors:  Brisa S Fernandes; Yulin Dai; Peilin Jia; Zhongming Zhao
Journal:  Eur Neuropsychopharmacol       Date:  2022-06-25       Impact factor: 5.415

Review 6.  Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.

Authors:  Brian J Miller; David R Goldsmith
Journal:  Neuropsychopharmacology       Date:  2016-09-22       Impact factor: 7.853

7.  Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia.

Authors:  Arsen Arakelyan; Roksana Zakharyan; Aren Khoyetsyan; David Poghosyan; Rouben Aroutiounian; Frantisek Mrazek; Martin Petrek; Anna Boyajyan
Journal:  BMC Clin Pathol       Date:  2011-08-25

8.  Inflammatory Pathways in Psychiatric Disorders: The case of Schizophrenia and Depression.

Authors:  Tami Feng; Ashutosh Tripathi; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2020-07-26

Review 9.  Innate immunity and neuroinflammation.

Authors:  Abhishek Shastri; Domenico Marco Bonifati; Uday Kishore
Journal:  Mediators Inflamm       Date:  2013-06-15       Impact factor: 4.711

Review 10.  Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis.

Authors:  Meike Heurich; Melanie Föcking; David Mongan; Gerard Cagney; David R Cotter
Journal:  Mol Psychiatry       Date:  2021-07-05       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.